The death of PD-L1 in urothelial cancer
At the 2018 ASCO Genitourinary Cancer Symposium, one of the standout keynote lectures was from Professor Tom Powles, Director of the Bart’s Cancer Cancer Center in London who talked about “Immune checkpoint inhibitors in Urothelial Cancer: which one and why?”
We’ve been following the highs and lows around checkpoint inhibitors in bladder cancer for some time, so it was interesting to hear what Prof Powles had to say in San Francisco.
How does he see the landscape evolving for immune checkpoint inhibitors?
To learn more and get a heads up on our latest oncology and conference insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
